Am J Transplant, Volume 19, Suppl 3 Archives - Page 56 of 214 - ATC Abstracts

2019 American Transplant Congress
A Comprehensive and Updated Analysis of Combined Heart-Kidney Transplants Utilizing the United Network for Organ Sharing Database
V. M. Lim¹, N. Khurmi¹, W. R. Hewitt, Jr.², A. K. Mathur², O. E. Pajaro³, D. E. Jaroszewski³, B. D. Gaitan¹
¹Anesthesiology, Mayo Clinic Arizona, Phoenix, AZ, ²Transplantation Surgery, Mayo Clinic Arizona, Phoenix, AZ, ³Cardiovascular and Thoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ
*Purpose: Analysis of combined heart-kidney transplants (HKTx) reveals equivalent or improved patient survival and reduced allograft rejection rates as compared to single-organ transplants. The rate…
2019 American Transplant Congress
Belatacept Monotherapy in Kidney Transplant Recipients with Failed Allografts Reduces Humoral Sensitization in a Single Center Randomized Controlled Trial
I. R. Badell, R. Elbein, R. A. Bray, H. M. Gebel, A. B. Adams, C. P. Larsen
Emory University School of Medicine, Atlanta, GA
*Purpose: Kidney transplant recipients with failed allografts suffer from high rates of humoral sensitization. Immunosuppression (IS) strategies are highly variable in these patients with many…
2019 American Transplant Congress
AKI and Long-Term Risk for Cardiovascular Events in Patients after Kidney Transplantation
R. Rahamimov¹, M. Molcho², I. Vahav², E. Mor³, T. Y. van Dijk⁴, B. Rozen-Zvi¹
¹Department of Nephrology, Rabin Medical Center, Petach Tikva, Israel, ²Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ³Department of Transplantation, Rabin Medical Center, Petach Tikva, Israel, ⁴Department of Emergency Medicine, Rabin Medical Center, Petach Tikva, Israel
*Purpose: AKI was found to be associated with increased risk of major cardiovascular events (MACE) in the general population. Patients after kidney transplantation are prone…
2019 American Transplant Congress
Epstein Barr Virus (EBV)-Specific T Cells as a Diagnostic Marker for the Individual EBV-Specific Immune Response after Pediatric Kidney Transplantation
T. Ahlenstiel-Grunow, L. Pape
Pediatric Nephrology, Hannover Medical School, Hannover, Germany
*Purpose: After transplantation immunosuppressive therapy causes an impaired cellular immune response resulting in an increased risk of EBV-associated complications, e.g. post-transplant lymphoproliferative disease (PTLD). Prognostic…
2019 American Transplant Congress
A Metagene Signature of Lymphocytic Bronchitis Following Lung Transplantation
J. R. Greenland¹, P. Wang², J. J. Brotman², R. Ahuja¹, T. A. Chong², M. Kleinhenz², L. E. Leard², J. A. Golden², S. R. Hays², J. P. Singer², J. Kukreja³, N. Y. Greenland⁴, Z. Lasik⁴, P. Blanc¹
¹Medicine, VA Health Care System, San Francisco, CA, ²Medicine, University of California, San Francisco, CA, ³Surgery, University of California, San Francisco, CA, ⁴Pathology, University of California, San Francisco, CA
*Purpose: Lymphocytic bronchitis (LB) precedes chronic lung allograft dysfunction (CLAD). Peri-vascular (A-grade) and peri-bronchiolar (B-grade) lymphocytic inflammation are traditional markers of acute cellular rejection. The…
2019 American Transplant Congress
Implication of Melanocortin Receptors in Alloimmunity
M. Uehara, B. S. Al Dulaijan, J. Azzi, R. Abdi
Transplantation Research Center, Renal, Brigham and Women's Hospital, Boston, MA
*Purpose: Recent studies have indicated the importance of the melanocortin pathway in the regulation of immune responses. In particular, the role that melanocortin receptors (MCRs)…
2019 American Transplant Congress
Not All Poor Metabolizers Are Clinically Equal: Evaluating Weight-Based Tacrolimus Outcomes in CYP3A Loss of Function Variants
A. Q. Maldonado, W. Irish, T. E. Asempa, J. Gooden, M. L. Davis, C. Haisch, H. Jones, D. Leeser, L. Rebellato
Vidant Medical Center - Transplant Services, Greenville, NC
*Purpose: CYP3A polymorphisms are an important pharmacotherapeutic consideration due to the extensive CYP metabolism of tacrolimus (TAC) and variable expression among different races. The CPIC…
2019 American Transplant Congress
Actions Speak Louder Than Labs – The Impact of Dialysis Compliance on Posttransplant Outcomes
D. Sawinski¹, H. Lindner², J. Schults³, J. Locke⁴, P. Reese¹
¹Hospital of the U of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Pennsylvania, Philadelphia, PA, ⁴University of Alabama at Birmingham, Birmingham, AL
*Purpose: Non-adherence is a modifable risk factor for poor posttransplant outcomes. While the factors contributing to posttransplant non-adherence are complex, noncompliance with the dialysis prescription…
2019 American Transplant Congress
Response to Treatment in Kidney Recipients with Acute T Cell-Mediated Rejection: Major Impact of Inflammation in Sclerotic Cortical Parenchyma (i-IF/TA) and Donor-Specific Antibodies
Y. Bouatou, D. Viglietti, D. Pievani, J. Duong Van Huyen, O. Aubert, D. Glotz, C. Legendre, A. Loupy, C. Lefaucheur
Paris Translational Research Center for Organ Transplantation, Paris, France
*Purpose: The recent recognition of chronic TCMR phenotypes has fostered the need to better evaluate the response of acute TCMR to standard-of-care treatment.*Methods: Among 2905…
2019 American Transplant Congress
Higher Level of Social Support is Associated with Higher Likelihood of Pursuit of Living Donor Kidney Transplant (LDKT)
T. Ahmed¹, S. Dano¹, Z. Zhou¹, I. Unarain¹, M. Saqib¹, V. Li¹, Y. Khoo¹, M. Novak², I. Mucsi¹
¹Multi-Organ Transplant Program and Division of Nephrology, University Health Network, Toronto, ON, Canada, ²Centre for Mental Health, University Health Network, Toronto, ON, Canada
*Purpose: LDKT is the optimal treatment for many patients with End Stage Kidney Disease (ESKD) , offering better clinical outcomes and quality of life. Studies…